Therapy

Why?

• Patients with severe congestive heart failure and anaemia who receive milrinone compared with placebo are more likely to develop new atrial flutter or fibrillation or sustained hypotension, and do not spend less time in hospital. ^a

Milrinone causes arrhythmias and hypotension

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNH (95% CI)
severe congestive heart failure a	milrinone	placebo	new atrial fibrillation or flutter at 2 months	1.5%	-210% (-620% to -34%)	32 (19 to 100)
			sustained hypotension at 2 months	3.2%	-240% (-490% to -92%)	13 (9 to 23)